Výsledky vyhledávání - "Oana Cristina Danciu"

Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity

Autor: Rakesh Sathish Nair, Sandeep Kumar, Navin Viswakarma, Rajyasree Emmadi, Basabi Rana, Periannan Sethupathi, Oana Cristina Danciu, Ajay Rana, Sunil Kumar Singh, Gautam Sondarva, Gregory R. J. Thatcher, Subhash C. Sinha, Kent Hoskins

Publikováno v: Proc Natl Acad Sci U S A

Mixed lineage kinase 3 (MLK3), also known as MAP3K11, was initially identified in a megakaryocytic cell line and is an emerging therapeutic target in cancer, yet its role in immune cells is not known. Here, we report that loss or pharmacological inhi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230fd782498115f0ede2ac33e4bed394
https://doi.org/10.1073/pnas.1921325117

Zobrazit plný text záznamu

Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

Autor: Oana Cristina Danciu, Sujata Gaitonde, Rozina A. Chowdhery, Arkadiusz Z. Dudek, Rajyasree Emmadi, Neeta K. Venepalli, James H. Fischer, Nathan Aardsma, Meredith J Russell, Rajul Kothari, Li C Liu, Robert J. Cabay, Ayesha J Zaidi

Publikováno v: American Journal of Clinical Oncology. 42:862-869

Objectives Insulin-like growth factor-methotrexate (IGF-MTX) is a conjugate of methotrexate and 765IGF, a variant of IGF-1 with high affinity for insulin-like growth factor type 1 receptor. The study aim was to determine the maximum tolerated dose of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ee5a49deb2f4b888f605ebd5bc23b5a
https://doi.org/10.1097/coc.0000000000000611

Zobrazit plný text záznamu

Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer

Autor: Sneha Deepak Phadke, Menggang Yu, Kathy Miller, Ami N. Shah, Oana Cristina Danciu, Kari Braun Wisinski

Publikováno v: Journal of Clinical Oncology. 40:e13075-e13075

e13075 Background: Metastatic triple negative breast cancer (TNBC) is a disease subtype with a poor prognosis, though advancements have been made in the use of targeted therapies, such as poly (ADP-ribose) polymerase inhibitors (PARPi) for those with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a66c14449ba9e86d55d3fd6df2e0b0e3
https://doi.org/10.1200/jco.2022.40.16_suppl.e13075

Zobrazit plný text záznamu

Abstract OT3-05-10: A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Autor: Li Liu, Deimante Tamkus, Deborah Toppmeyer, Kent Hoskins, Oana Cristina Danciu, Anne H. Blaes, Kari B. Wisinski, Cristina I. Truica, Lauren Green

Publikováno v: Cancer Research. 78:OT3-05

Background: Hormone receptor positive breast cancer is the most commonly diagnosed subset of breast cancer (60-65%). Endocrine therapy is effective for this subset of breast cancer, in both the adjuvant and metastatic settings. Despite advances in en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fd92ad07ff6b360e97fb5b9bda4e493
https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-10

Zobrazit plný text záznamu

ACTR-63. PHASE I DOSE ESCALATION STUDY OF PROCASPASE ACTIVATING COMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA

Autor: Oana Cristina Danciu, Matthias Holdhoff, Theodore M. Tarasow, Arkadiusz Z. Dudek, Paul J. Hergenrother, Martin K. Nicholas, Richard A. Peterson, Stefania Maraka

Publikováno v: Neuro Oncol

BACKGROUND Procaspase activating compound -1 (PAC-1) is a small molecule that catalyzes conversion of procaspase-3 to caspase-3 which induces apoptosis in cancer cells. Glioblastoma (GBM) is among the tumors with high concentrations of procaspase-3 a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2b1446056fb689ac9638fade66fb41
https://europepmc.org/articles/PMC6847026/

Zobrazit plný text záznamu

Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors

Autor: James H. Fischer, Hiral A. Shah, Sonia Christian, Neeta K. Venepalli, Li C Liu, Oana Cristina Danciu, James P. Zacny, Arkadiusz Z. Dudek, Meredith J Russell

Publikováno v: American journal of clinical oncology. 42(5)

Objectives Pazopanib is a multikinase angiogenesis inhibitor. Alisertib is a highly selective inhibitor of mitotic Aurora A kinase. There is preclinical evidence that mitosis-targeting agents exhibit antiangiogenic effects. Thus, the combination of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f74456a3da2249aebdd3d12dc0f04ef
https://pubmed.ncbi.nlm.nih.gov/30973373

Zobrazit plný text záznamu

Disparities within luminal breast cancer: Clinical and molecular features of African American and non-Hispanic white patients

Autor: Vijayakrishna K. Gadi, Dipali Sharma, Oana Cristina Danciu, Yael Simons, Heather M. Kling, Sahra Uygun, Lisa Blumencranz, Mehran Habibi, Kent Hoskins, William Audeh, Jennifer A. Crozier

Publikováno v: Journal of Clinical Oncology. 39:1009-1009

1009 Background: African American breast cancer patients (AA) are diagnosed younger, have more high-risk features, and poorer clinical outcomes than non-Hispanic White patients (NHW), despite similar treatments. Although comorbidities such as obesity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23cab767f4cb7ed8ea4d3100cf138217
https://doi.org/10.1200/jco.2021.39.15_suppl.1009

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání